Randomized phase II trial of erlotinib beyond progression in advanced erlotinib-responsive non-small cell lung cancer
Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
Effect of smoking status on progression‐free and overall survival in non‐small cell lung cancer patients receiving erlotinib or gefitinib: a meta‐analysis
HS Sohn, JW Kwon, S Shin, HS Kim… - Journal of Clinical …, 2015 - Wiley Online Library
What is known and objective Epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR‐TKIs) such as erlotinib or gefitinib are indicated for the treatment of non‐small cell …
(EGFR‐TKIs) such as erlotinib or gefitinib are indicated for the treatment of non‐small cell …
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC
GR Oxnard, VA Miller - Oncology, 2010 - search.proquest.com
Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …
Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L
Y Urata, N Katakami, S Morita, R Kaji… - Journal of Clinical …, 2016 - ascopubs.org
Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer
A Horiike, N Yamamoto, H Tanaka… - Anticancer …, 2014 - ar.iiarjournals.org
Background: Gefitinib and erlotinib are used to treat advanced non-small cell lung cancer
(NSCLC). Gefitinib is a common first-line treatment, but most patients develop resistance …
(NSCLC). Gefitinib is a common first-line treatment, but most patients develop resistance …
Erlotinib in the first-line treatment of non-small-cell lung cancer
M D'Arcangelo, F Cappuzzo - Expert review of anticancer therapy, 2013 - Taylor & Francis
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths. In the
last decade the EGF receptor (EGFR) signaling pathway has emerged as one of the most …
last decade the EGF receptor (EGFR) signaling pathway has emerged as one of the most …
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
Y Wang, G Schmid-Bindert… - Therapeutic advances in …, 2012 - journals.sagepub.com
Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials
M Burotto, EE Manasanch, J Wilkerson, T Fojo - The oncologist, 2015 - academic.oup.com
Abstract Background. Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …
EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case–control …
M Faehling, R Eckert, T Kamp, S Kuom, U Griese… - Lung cancer, 2013 - Elsevier
INTRODUCTION: Some patients with advanced NSCLC show prolonged disease
stabilization on treatment with an EGFR-tyrosine kinase inhibitor (TKI) such as erlotinib. It is …
stabilization on treatment with an EGFR-tyrosine kinase inhibitor (TKI) such as erlotinib. It is …
Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
Y Togashi, H Hayashi, K Nakagawa… - Drug design …, 2014 - Taylor & Francis
Gefitinib, an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), has been
approved in Japan for the treatment of patients with advanced non-small-cell lung cancer …
approved in Japan for the treatment of patients with advanced non-small-cell lung cancer …